Intec Pharma (NTEC) & The Competition Critical Comparison

Intec Pharma (NASDAQ: NTEC) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Intec Pharma to related businesses based on the strength of its analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Insider and Institutional Ownership

40.2% of Intec Pharma shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Intec Pharma and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intec Pharma 0 0 4 0 3.00
Intec Pharma Competitors 887 3274 11772 235 2.70

Intec Pharma currently has a consensus price target of $12.00, indicating a potential upside of 133.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.56%. Given Intec Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Intec Pharma is more favorable than its competitors.

Valuation and Earnings

This table compares Intec Pharma and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intec Pharma N/A -$13.36 million -4.40
Intec Pharma Competitors $284.49 million $34.10 million 62.56

Intec Pharma’s competitors have higher revenue and earnings than Intec Pharma. Intec Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Intec Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intec Pharma N/A N/A N/A
Intec Pharma Competitors -5,248.95% -210.61% -37.96%

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

What are top analysts saying about Intec Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intec Pharma and related companies.

Intec Pharma (NTEC) & The Competition Critical Comparison

Intec Pharma (NASDAQ: NTEC) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Intec Pharma to related businesses based on the strength of its analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Insider and Institutional Ownership

40.2% of Intec Pharma shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Intec Pharma and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intec Pharma 0 0 4 0 3.00
Intec Pharma Competitors 887 3274 11772 235 2.70

Intec Pharma currently has a consensus price target of $12.00, indicating a potential upside of 133.01%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.56%. Given Intec Pharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Intec Pharma is more favorable than its competitors.

Valuation and Earnings

This table compares Intec Pharma and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intec Pharma N/A -$13.36 million -4.40
Intec Pharma Competitors $284.49 million $34.10 million 62.56

Intec Pharma’s competitors have higher revenue and earnings than Intec Pharma. Intec Pharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Intec Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intec Pharma N/A N/A N/A
Intec Pharma Competitors -5,248.95% -210.61% -37.96%

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The Company is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.

What are top analysts saying about Intec Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intec Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit